← Leaderboards
Matthew W Kalnik
Antidote Therapeutics, Inc.
$21,780,207
Attributed
$21,780,207
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.2M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,780,207 · 3
By mechanism
U01$13,125,765 · 1
R01$8,453,608 · 1
R43$200,834 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Standard Of Care”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Larry Arthur$176,170,000
- Philip J Disaia · University Of California Irvine$160,519,236
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$153,280,930
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$146,506,952
Research focus
Standard Of CareMonoclonal AntibodiesSmokingSmoking CessationNicotine DependenceNicotineHalf-LifeSmokerPharmacotherapyPharmaceutical PreparationsBrainHealth Care CostsIn VivoPre-ClinicalAddictionCessation Of LifeCigarette SmokingPlacebosMedicalPreparationAntibodiesHuman Monoclonal AntibodiesPrivate SectorMeetings
Grant awards (7)
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$3,883,739
U01 · FY2025 · DA · contact PI
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$5,215,321
U01 · FY2024 · DA · contact PI
IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody$4,026,705
U01 · FY2023 · DA · contact PI
Protein Engineering of a Biologic Drug Candidate$200,834
R43 · FY2017 · DA · contact PI
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,939,717
R01 · FY2016 · DA · contact PI
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,960,853
R01 · FY2015 · DA · contact PI
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs$2,553,038
R01 · FY2014 · DA · contact PI